Genzyme Corp. will not walk away from GZMO and its tremendous IP portfolio, clinical trials, and collaborations. GZMO has many options for raising additional capital. Also, despite what some would have you think, not all of these options are dilutive to shareholder value. GZMO is in a better position than virtually all of its small cap competitors. I'm not worried. Genzyme will stay the course.